The Study Of Association Between CYP2D6*10 Genotype And Efficacy In Estrogen-Receptor Positive Breast Cancer Patients Receiving Tamoxifen Treatment

Background:Human cytochrome P450 2D6 (CYP2D6) genotype may affect the efficacy of tamoxifen treatment in Caucasian women with breast cancer. The most common polymorphism of CYP2D6 in Chinese women is variant 10(188 C to T).Purpose:Investigated the association between CYP2D6*10 genotype and efficacy in Estrogen-Receptor positive breast cancer patients receiving tamoxifen treatment We evaluat the predictive value of genetic variants of cytochrome P450 enzymes CYP2D6 for tamoxifen treatment outcome.Method:DNA from 123 patients who taking TAM and was genotyped for CYP2D6*10 by using polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) method, Risk and survival estimates were calculated using Kaplan-Meier, and Cox regression analyses.statistical analysis using SPSS 16.0 software, testing level ofα= 0.05.Result:123 patients,17 patients had local recurrence or distant metastasis,7 cases of breast cancer deaths.Drawn by the Kaplan-Meier method of survival curve,Log-rank test, the CYP2D6*10 genotype was not significantly associated with DFS and DSS in the C/T and C/C genotype, the T/T genotype three subgroups (P values were 0.425,0.470 respectively).But in multivariate analysis, as compared with the C/T and C/C genotype, the T/T genotype remained an independent prognostic marker of DFS(HR=3.429;95% CI 1.143～10.285 P=0.028),but no correlation with DSS (P=0.636).Conclusion:CYP2D6*10 genotype and taking TAM estrogen receptor-positive breast cancer patients with DFS-related, and is an independent prognostic factor.According to the CYP2D6*10 genotype on the clinical use of drugs.TAM individualized guidance is feasible in breast cancer patients.